Aegis Capital Lifts PT on Navidea Biopharma (NAVB) to $2.50; Lymphoseek Sales Encouraging
Tweet Send to a Friend
Aegis Capital is raising its price target on Navidea Biopharmaceuticals, Inc (AMEX: NAVB) by 25 percent from $2 to $2.50 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
